Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Malignant Neoplasm of Uterus

Icahn School of Medicine at Mount SinaiSmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

46 Active assets in the Malignant Neoplasm of Uterus cohort.

Asset / SponsorPhaseRating
Ferrous Fumarate
Sunnybrook Health Sciences Centre
Phase 4BB
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Gynecologic Oncology Associates
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
University of California, Irvine
Phase 3B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Dkn-01
Leap Therapeutics, Inc.
Phase 2B

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →